EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Defibrotide for the Treatment of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome with Multiorgan Failure

Paul G Richardson, Stephan A Grupp, Antonio Pagliuca, Amrita Krishnan, Vincent T Ho, Selim Corbacioglu

International Journal of Hematologic Oncology · 2017

DOI: 10.2217/ijh-2017-0015 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Hematologic Oncology, 2017. Verfasst von Paul G Richardson und 5 weiteren Autor:innen. Beteiligte Einrichtung: Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 82 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hepatic veno-occlusive disease, also called sinusoidal obstruction syndrome (VOD/SOS), is a potentially life-threatening and unpredictable complication of hematopoietic stem cell transplantation (HSCT). Characterized by a prothrombotic-hypofibrinolytic state, VOD/SOS typically presents with hyperbilirubinemia, ascites, weight gain and painful hepatomegaly; VOD/SOS with multiorgan failure may be associated with >80% mortality. Treatment has been mainly supportive. However, defibrotide is now approved in the USA for treatment of hepatic VOD/SOS with renal or pulmonary dysfunction following HSCT and in the European Union for treatment of severe hepatic VOD/SOS post-HSCT. In vitro evidence suggests defibrotide may restore thrombotic-fibrinolytic balance at the endothelial level and protect endothelial cells. Defibrotide has demonstrated significant reduction in VOD/SOS-related mortality and resolved VOD/SOS-related symptoms, with a manageable safety profile.

Schlagwörter

Stichwörter der Autor:innen

defibrotidediagnostic criteriaefficacymechanism of actionmultiorgan dysfunctionpathophysiologysafetysinusoidal obstruction syndrometreatmentveno-occlusive disease

Autor:innen und Institutionen

  • Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
  • Pediatric Oncology, The Children's Hospital of Philadelphia & the Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
  • Department of Haematological Medicine, King's College Hospital, London, UK.
  • Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA, USA.
  • Hematopoietic Stem Cell Transplantation, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Department of Pediatric Hematology, Oncology & Stem Cell Transplantation, University of Regensburg, Regensburg, Germany.

Zitieren

APA

Richardson, P. G., Grupp, S. A., Pagliuca, A., Krishnan, A., Ho, V. T., & Corbacioglu, S. (2017). Defibrotide for the Treatment of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome with Multiorgan Failure. International Journal of Hematologic Oncology. https://doi.org/10.2217/ijh-2017-0015

Vancouver

Richardson PG, Grupp SA, Pagliuca A, Krishnan A, Ho VT, Corbacioglu S. Defibrotide for the Treatment of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome with Multiorgan Failure. International Journal of Hematologic Oncology. 2017. doi:10.2217/ijh-2017-0015

BibTeX
@article{Richardson2017,
  author = {Richardson, Paul G and Grupp, Stephan A and Pagliuca, Antonio and Krishnan, Amrita and Ho, Vincent T and Corbacioglu, Selim},
  title = {Defibrotide for the Treatment of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome with Multiorgan Failure},
  journal = {International Journal of Hematologic Oncology},
  year = {2017},
  doi = {10.2217/ijh-2017-0015}
}
Kostenlos starten →